PROTOCOL SPECIFIC RESEARCH SUPPORT

特定于协议的研究支持

• 批准号: 8765187
• 负责人: William L. Carroll
• 金额: $ 0.86万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8765187
• 关键词: Accounting; Area; Breast; Cancer Center; Cancer Center Support Grant; Cancer Control; Categories; Clinical Trials; Collaborations; Development; Developmental Therapeutics Program; Disease Management; Faculty; Fostering; Funding; Future; Goals; Grant; Gynecologic Oncology; Institutes; Instruction; Laboratories; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Mentorship; Monitor; Patients; Pediatric Oncology; Phase; Population Sciences; Protocols documentation; Radiation Oncology; Recommendation; Recruitment Activity; Research; Research Personnel; Research Support; Resources; Scientific Advances and Accomplishments; Surgical Oncology; Therapeutic; Therapy Clinical Trials; Thoracic Oncology; design; interdisciplinary collaboration; meetings; neuro-oncology; novel; pilot trial; prevent; programs

PROJECT SUMMARY (See instructions): CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Approximately 23% of NYUCI therapeutic trials are Investigator-Initiated Trials. Accrual to investigator-initiated studies at NYUCI has increased by almost 10% over the last funding period and this category now accounts for 68.6% of all therapeutic accruals. Protocols considered for PSRS funds have to meet the following requirements: 1) Designation of high priority by a NYUCI Disease Management Group and/or CCSG Scientific Research Program; 2) Approval and high merit score by the Protocol Review & Monitoring Committee (PRMC); 3) Clearance provided by the Clinical Trials Office that all other institutional requirements and investigator's conduct of research are met; and 4) Recommendation by the PRMC, Cancer Institute Director and CCIC for funding. The CCIC, in conjunction with the PSRS Chair, review all relevant approvals, scores, and the financial assessment of the trial to make the determination about PSRS funding.

项目摘要（请参阅说明）： 用于协议特定研究支持（PSR）的CCSG资金用于开发Nyuci研究者启动的早期阶段协议。 Nyuci在此类研究中占优先，因为它们代表了NCI癌症中心计划中最有希望的好处之一。 Nyuci治疗试验中约有23％是研究者发起的试验。在上一个资金期间，对Nyuci研究者发起的研究的应计增长了近10％，现在该类别占所有治疗额的68.6％。 考虑到PSRS资金的协议必须满足以下要求： 1）NYUCI疾病管理小组和/或CCSG科学研究计划指定高优先级； 2）协议审查与监测委员会（PRMC）的批准和高价评分； 3）临床试验办公室提供的清算，所有其他机构要求和 调查人员的研究行为得到满足；和 4）PRMC，癌症研究所主任和CCIC资助的建议。 CCIC与PSRS主席一起审查了所有相关批准，分数和经济评估，以确定PSRS资金。